

ASX RELEASE

Global Expansion Continues: Sienna enters Greek market with hTERT IVD

- Aenorasis S.A. appointed exclusive distributor in Greece and Cyprus
- Aenorasis has net annual turnover of €34.9 million and was awarded the Bousias Communications Golden Distinction Healthcare Business Award in Greece (2019)¹
- Bladder cancer is globally the sixth most commonly occurring cancer in men and the 17th in women²
- Greece recorded 2,100 new cases in 2018 and has the second highest rate of bladder cancer in the world after Lebanon²
- It is estimated that 10,000 urine cytology tests are performed annually in Greece and Cyprus.

Melbourne, Australia, 19 June 2020 (Melbourne, Australia): [Sienna Cancer Diagnostics Ltd \(ASX:SDX\)](#) (“Sienna” or “the Company”) is pleased to announce the appointment of Aenorasis S.A (“Aenorasis”) as its exclusive distributor in Greece and Cyprus. The distribution agreement provides Aenorasis with the right to sell Sienna’s hTERT IVD to pathology laboratories where it will be used to assist in the diagnosis of bladder cancer.

Aenorasis is a Greek pharmaceutical company that was established in 1965 and is a member of the ELPEN group of companies. The company offers a wide range of diagnostic and therapeutic solutions and is a leading distributor of medical devices, high-technology and high-precision products for all hospital units in Greece. Aenorasis is also an exclusive distributor for Hologic’s ThinPrep® liquid-based cytology products. These products are the upstream component of Sienna’s hTERT test, making the partnership between Sienna and Aenorasis a perfect fit for both companies.

Maria Halatsi, Marketing and Sales Director at Aenorasis, said: “There is a perfect synergy between the Hologic products and the hTERT ICC test. Aenorasis has years of experience implementing diagnostic tests in Greece and the expertise to promote a new diagnostic solution.”

Aenorasis CEO Sotiris Konstantakis said: “hTERT is a promising diagnostic test that will complement our existing product range. The hTERT ICC test will provide cyto-pathologists and clinicians with important adjunct information to assist in detecting bladder cancer at an early stage, resulting in better patient management.”

Sienna will soon begin sales and technical training with Aenorasis staff, in addition to setting up two reference laboratories in Greece. Aenorasis is Sienna’s fifth distributor appointment in 2020 as the Company continues its overseas expansion.

Sienna’s Business Development Manager, Minesh Lalla, said: “At the International Cytology Congress in Sydney in May 2019, Sienna presented case studies evaluating the clinical utility of hTERT in detecting low-grade disease to the Aenorasis team, who saw its potential for the Greek market. Since hTERT is already CE Marked, Sienna and Aenorasis can begin promoting the test immediately.”

ENDS.

¹ Aenorasis company website: https://www.aenorasis.com/news_press_releases/healthcare-business-awards-2019/

² World Cancer Research Fund International <https://www.wcrf.org/dietandcancer/cancer-trends/bladder-cancer-statistics>

For Further Information, please contact:

Carl Stubbings, CEO & Managing Director

Sienna Cancer Diagnostics Ltd

cstubbings@siennadiagnostics.com.au

+61 3 8288 2141

The release of this announcement was authorised by Tony Di Pietro, Company Secretary.

About Sienna Cancer Diagnostics Ltd.

Sienna is a medical technology company that develops and commercialises diagnostic tests to assist in the early and accurate diagnosis of cancer, enabling improved treatment and patient outcomes. Sienna's first product, hTERT, a test that aids in the diagnosis of bladder cancer, has been launched and is being commercialised through a growing network of distribution partners globally.

Sienna entered the global liquid biopsy market in 2019 via the strategic acquisition of a "Molecular Net" technology called SIEN-NET™. The first commercial embodiment of SIEN-NET is EXO-NET™, which has been specifically designed to purify a patient sample for cancer-associated exosomes.

The Company recently announced the signing of an exclusive worldwide licence agreement with the University of Adelaide to develop and commercialise a unique cancer probe, SubB2M, which binds to a unique sugar molecule only present in human cancers and can detect its presence in the serum of cancer patients. SubB2M has the potential to detect cancer in a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.

Forward Looking Statements

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.